HBIO Announces Filing of Request for Acceleration of Effectiveness for Harvard
Apparatus Regenerative Technology, Inc.'s IPO Registration Statement
HOLLISTON, Mass., April 2, 2013 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc.
(Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range
of tools to advance life science research and regenerative medicine, today
announced that its wholly-owned subsidiary, Harvard Apparatus Regenerative
Technology, Inc., filed a request for acceleration of effectiveness of its
registration statement on Form S-1 with the Securities and Exchange Commission
in connection with the initial public offering, or IPO, of Harvard Apparatus
Regenerative Technology's common stock.
This release is available on our website by clicking on the Press Releases
A registration statement including a prospectusrelating to the common stock
of Harvard Apparatus Regenerative Technology, Inc. has been filed with the SEC
but has not yet become effective. These securities may not be sold nor may
offers to buy these securities be accepted before the time the registration
statement becomes effective. This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.
The initial public offering will be made only by means of a written prospectus
meeting the requirements of Section 10 of the Securities Act of 1933.Before
you invest in Harvard Apparatus Regenerative Technology, you should read the
prospectus in that registration statement and the documents filed as exhibits
to the registration statement for more complete information about Harvard
Apparatus Regenerative Technology. You may get these documents for free by
visiting EDGAR on the SEC web site at www.sec.gov. Alternatively, a copy of
the preliminary prospectus may be obtained from the offices ofSummer Street
Research Partners, Attention: Prospectus Department, 101 Arch Street, Boston,
MA 02110 or by telephone at +1-617-532-6464.
Some of the statements in this press release are "forward-looking" and are
made pursuant to the safe harbor provision of the Private Securities
Litigation Reform Act of 1995. These "forward-looking" statements include
statements relating to, among other things, the planned IPO and the potential
spin-off from Harvard Bioscience of Harvard Apparatus Regenerative Technology.
These statements involve risks and uncertainties, including among other
things, market conditions and with respect to the possible spin-off, Harvard
Bioscience's ability to obtain a private letter ruling from the Internal
Revenue Service regarding the distribution's tax-free treatment, that may
cause results to differ materially from the statements set forth in this press
release. The forward-looking statements in this press release speak only as of
the date of this press release and are subject to uncertainty and changes.
Given these circumstances, you should not place undue reliance on these
forward-looking statements. Harvard Bioscience expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to such
statements to reflect any change in its expectations with regard thereto or
any changes in the events, conditions or circumstances on which any such
statement is based.
For investor inquiries, please call (508) 893-8066. Press releases may be
found on our web site, http://www.harvardbioscience.com.
The Harvard Bioscience, Inc. logo is available at
CONTACT: David Green
Tel: 508 893 8999
Fax: 508 429 8478
Harvard Bioscience, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.